drugset / Trial / NCT03645928
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.
Timeline
- Start
- 2019-05-07
- Primary completion
- 2026-02-20
- Completion
- 2026-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | LN-145-S1 | Cell therapy | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Relatlimab | Monoclonal antibody | — | — |
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | — | — |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | Intravenous |